The authors hypothesized that certain microenvironmental conditions, such as anti-cancer therapy or oxidative stress, can increase the functional demands for this CD24+CD271+ subpopulation, and therefore, melanoma CSCs can undergo phenotype switching, allowing them to adapt to therapeutic pressures and maintain tumor growth despite treatment [112]. Here, CD24 is linked to melanoma.